THE NEW ERA OF THALASSEMIA SYNDROMES: IS IT TIME TO
Transcript
THE NEW ERA OF THALASSEMIA SYNDROMES: IS IT TIME TO
Invited Speakers: Kunle Adekile M. B. Agarwal Abdulla Al Jefri Yesim Aydinok Caterina Borgna Pignatti Maria Domenica Cappellini Marina Cavazzana-Calvo Adriana Ceci Alan Cohen Shahina Daar Vito Di Marco Amal El-Beshlawy John Fang Aldo Filosa Gian Luca Forni Suthat Fucharoen Mahmoud Hajipour Olivier Hermine Ibrahim Hishamshah Mehran Karimi Antonis Kattamis Aurelio Maggio Khaled Musallam Dudley Pennell Alessia Pepe Antonio Piga John Porter Vijay G. Sankaran Farrukh Shah Alok Srivastava Ali Taher Paul Telfer Vip Viprakasit ... Who John Wood Mahmoud Yassin Kuwait India KSA Turkey Italy Italy France Italy USA Oman Italy Egypt China Italy Italy Thailand Iran France Malaysia Iran Greece Italy Uk UAE Uk Italy Italy Uk USA KSA India Lebanon Uk Thailand ... ... Qatar CME Provider and Organizing Secretariat Via U. Giordano, 37/A - 90144 Palermo - Italy - Tel. +39 091 6867.401 - Fax +39 091 9889354 e-mail: [email protected] - web: www.collage-spa.it THE NEW ERA OF THALASSEMIA SYNDROMES: IS IT TIME TO REVISIT CLINICAL CLASSIFICATION OF THE THALASSEMIAS ? September 15-16, 2017 CAMPUS OF HEMATOLOGY "Franco e Piera Cutino" A.O.R. "Villa Sofia - V. Cervello" Palermo (Italy) FIRST ANNOUNCEMENT Chairmen: Antonis Kattamis, Ali Taher, Khaled Musallam and Aurelio Maggio Rationale Recent data suggest that the survival of well-treated patients with Thalassemia Major is now similar to that of Intermediate Thalassemia Intermedia (Vitrano et al., 2016, BJH). In addition, retrospective data on 4.943 subjects with a heterozygote state of beta-thalassemia, suggest that, even in patients defined as thalassemia carriers (Thalassemia Minor), there is an increase in morbidity (cirrhosis, kidney disease, etc.) compared with the non-thalassemic population of subjects not heterozygote (Graffeo et al., AJH, in press). These data call for a potential revision of the clinical classification of thalassemia based on strict categories of severity towards a classification including a "continuum" of the same disease divided into that manifests in stages. The advantages of this new classification would consist of: 1) expand the use of chelation therapy and transfusion to the ‘traditionally’ less severe forms of thalassemia syndromes or whose management was not commonly considered; 2) reduce the morbidity and mortality of such less severe forms of thalassemia syndromes; 3) reduce health care costs associated with the treatment of these uncontrolled complications (cirrhosis, etc.) through prevention; 4) expand the number of patients who are eligible to innovative therapies; 5) review the indications for prenatal diagnosis in Thalassemia Major. Main Topics • Thalassemia Major: how had conventional treatment been changing survival • Current survival of thalassemia in eastern countries: the Iran experience • Thalassemia Intermedia: is disease morbidity observed today less severe compared with thalasssemia major ? • The role of current chelation treatment in improving prognosis of thalassemia major and intermedia • The impact of new direct anti-viral treatment in improving prognosis of thalassemia syndromes • What is the impact of novel chelators or new formulations of available chelators treatments on outcomes in thalassemia syndromes? • Current state of total body iron burden in thalassemia major and thalassemia intermedia determined by MRI: what is the difference in terms of liver iron concentration? • Heart MRI T2* signal: a crucial tool for improving prognosis in thalassemia • Transfusion therapy: what has changed with respect to safety and control of iron loading? • How much are novel innovative therapies expected to influence the prognosis of thalassemia syndromes ? • Gene therapy for thalassemia and sickle-cell-disease: what is the future impact of this procedure on these diseases ? • “Cluster analysis” to differentiate thalassemia syndromes: report on 7843 subjects. Round Table: this will have the participation of all speakers to discuss and reconsider the current classification of thalassemia. Main Topics: Is the current dichotomy classification as thalassemia major and intermedia appropriate for management of these diseases? Is current access to thalassemia care limited by this current dichotomy classification? Is current availability of chelators a barrier for application of transfusion regimens in less severe phenotypes of thalassemia? Would re-classification of thalassemia in stages improve or worsen management outcomes? Could such new classification be more useful for allowing wider use of innovative treatment for thalassemia? The results of this meeting will be published as Special Issue on Anemia Journal!